SCD, a global pioeer in defence technology specialising in the development and manufacture of a wide range of cooled and ...

After a six-month wait, Fulcrum Therapeutics’ sickle cell disease (SCD) plans are back on track after the FDA lifted a hold on the biotech’s candidate. The regulator instigated the full clinical hold ...

Sickle cell disease (SCD) is not automatically a disability by law. However, people who experience debilitating symptoms may qualify for disability benefits, and several laws protect them from ...

Pfizer’s sickle cell disease (SCD) drug has flunked a key phase 3 test, the latest blow to the pharma’s $5.4 billion acquisition of Global Blood Therapeutics. Pfizer acquired the P-selectin inhibitor, ...